Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate

Both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) are common in the aging male. Numerous clinical trials have demonstrated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5-Is) for treating LUTS/BPH with/without ED. However,...

Full description

Bibliographic Details
Main Authors: Zhang, Wenhao, Zang, Ning, Jiang, Yaoming, Chen, Ping, Wang, Xinghuan, Zhang, Xinhua
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674741/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674741/

Similar Items